Connect Biopharmaceuticals Overview
- Year Founded
-
2012
- Status
-
Public
- Employees
-
64
- Stock Symbol
-
CNTB
- Share Price
-
$0.68
- (As of Friday Closing)
Connect Biopharmaceuticals General Information
Description
Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation antibody designed to target interleukin-4-receptor alpha. It is currently conducting clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD. The company operates in one operating segment: treatment of respiratory diseases.
Contact Information
Website
connectbiopharm.comCorporate Office
- East R&D Building, 3rd floor
- 6 Beijing West Road
- Taicang, Jiangsu 215400
- China
Corporate Office
- East R&D Building, 3rd floor
- 6 Beijing West Road
- Taicang, Jiangsu 215400
- China
Connect Biopharmaceuticals Stock Performance
As of 13-Nov-2026, Connect Biopharmaceuticals’s stock price is $0.68. Its current market cap is $42.6M with 63M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.68 | $0.67 | $0.64 - $3.82 | $42.6M | 63M | 3.92M | -$1.19 |
Connect Biopharmaceuticals Financials Summary
As of 30-Jun-2026, Connect Biopharmaceuticals has a trailing 12-month revenue of $2.95M.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 104,513 | 103,648 | (33,598) | (65,482) |
| Revenue | 2,953 | 64 | 26,033 | 0 |
| EBITDA | (69,612) | (56,847) | (19,198) | (66,489) |
| Net Income | (68,991) | (55,480) | (15,628) | (62,106) |
| Total Assets | 43,472 | 56,075 | 101,284 | 127,375 |
| Total Debt | 596 | 690 | 178 | 465 |
Connect Biopharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Connect Biopharmaceuticals Comparisons
Industry
Financing
Details
Connect Biopharmaceuticals Competitors (61)
One of Connect Biopharmaceuticals’s 61 competitors is Dicerna Pharmaceuticals, a Formerly VC-backed company based in Lexington, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Dicerna Pharmaceuticals | Formerly VC-backed | Lexington, MA | ||||
| Syndax | Formerly VC-backed | Waltham, MA | ||||
| ADC Therapeutics | Formerly VC-backed | Epalinges, Switzerland | ||||
| Incyte | Formerly VC-backed | Wilmington, DE | ||||
| Rigel Pharmaceuticals | Formerly VC-backed | South San Francisco, CA |
Connect Biopharmaceuticals Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Connect Biopharmaceuticals Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Connect Biopharmaceuticals Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Connect Biopharmaceuticals ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Pharmaceuticals
Subindustry
Rank
Percentile
Connect Biopharmaceuticals FAQs
-
When was Connect Biopharmaceuticals founded?
Connect Biopharmaceuticals was founded in 2012.
-
Where is Connect Biopharmaceuticals headquartered?
Connect Biopharmaceuticals is headquartered in Taicang, China.
-
What is the size of Connect Biopharmaceuticals?
Connect Biopharmaceuticals has 64 total employees.
-
What industry is Connect Biopharmaceuticals in?
Connect Biopharmaceuticals’s primary industry is Drug Discovery.
-
Is Connect Biopharmaceuticals a private or public company?
Connect Biopharmaceuticals is a Public company.
-
What is Connect Biopharmaceuticals’s stock symbol?
The ticker symbol for Connect Biopharmaceuticals is CNTB.
-
What is the current stock price of Connect Biopharmaceuticals?
As of 13-Nov-2026 the stock price of Connect Biopharmaceuticals is $0.68.
-
What is the current market cap of Connect Biopharmaceuticals?
The current market capitalization of Connect Biopharmaceuticals is $42.6M.
-
What is Connect Biopharmaceuticals’s current revenue?
The trailing twelve month revenue for Connect Biopharmaceuticals is $2.95M.
-
Who are Connect Biopharmaceuticals’s competitors?
Dicerna Pharmaceuticals, Syndax, ADC Therapeutics, Incyte, and Rigel Pharmaceuticals are some of the 61 competitors of Connect Biopharmaceuticals.
-
What is Connect Biopharmaceuticals’s annual earnings per share (EPS)?
Connect Biopharmaceuticals’s EPS for 12 months was -$1.19.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
